Trial Profile
An Observational Study to Evaluate Cardiovascular Outcomes of Patients With Type 2 Diabetes Mellitus Treated With Gemigliptin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2019
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors LG Chem; LG Life Sciences
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Jan 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 27 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.